Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.33) by 12.65 percent. This is a 50.85 percent increase over losses of $(0.59) per share from the same period last year. The company reported $11.038 million in sales this quarter.